About MuReva Phototherapy
MuReva’s mission is to create oral phototherapy devices that are inherently-safe, patient-friendly and clinically-proven to improve the quality of life and clinical outcomes for patients receiving radiation and chemotherapy for the treatment of cancer.
MuReva Phototherapy was established in 2018 and is committed to changing the way physicians approach cancer treatment by addressing key dose limiting side-effects for which there are currently only palliative solutions such as opioids. MuReva aims to not only improve patient outcomes, but also significantly increase patient quality of life while saving healthcare costs.
MuReva spun-off its parent company, Lumitex, a leader in fiber-optic lighting technologies, to focus on developing a patient-friendly approach for delivering phototherapy treatment. With the assistance of $1.7M in grant funding from the National Institutes of Health and an additional $1M+ in private funding, MuReva has developed a new light transmission modality to overcome the current barriers that have prevented its mainstream adoption. The company’s technology is not currently available for sale and is currently being studied as a part of a multicenter clinical trial in the U.S.
Our Leadership Team
MuReva Phototherapy’s leadership team is composed of experienced business executives and researchers who are responsible for defining and implementing the company’s strategy to offer a technology which improves patient outcomes.
Vedang Kothari, MEM
Sam Shelnutt, MBA
Austin Ruhle, MBA
Chief Financial Officer